ERAS-801
Phase 1Active 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma Multiforme
Conditions
Glioblastoma Multiforme
Trial Timeline
Feb 25, 2022 → Sep 30, 2025
NCT ID
NCT05222802About ERAS-801
ERAS-801 is a phase 1 stage product being developed by Erasca for Glioblastoma Multiforme. The current trial status is active. This product is registered under clinical trial identifier NCT05222802. Target conditions include Glioblastoma Multiforme.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05222802 | Phase 1 | Active |
Competing Products
20 competing products in Glioblastoma Multiforme